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http:WHAT THIS PAPER ADDS
Signiﬁcant increases in MCAV or PI following CEA could not predict patients at greatest risk of suffering an
intracranial haemorrhage or stroke due to the hyperperfusion syndrome. However, the provision of written
guidance for treating post-CEA hypertension appeared to be associated with virtual abolition of these major
complications.Objectives: To determine if signiﬁcant increases in middle cerebral artery velocity (MCAV) or Pulsatility Index (PI)
during and immediately after carotid endarterectomy (CEA) were predictive of patients suffering a stroke due to
the hyperperfusion syndrome (HS) or intracerebral haemorrhage (ICH).
Methods: Transcranial Doppler (TCD) mean/peak MCAV and PI were recorded pre-operatively; pre-clamp; 1-min
post-declamping; 10-min post-declamping and 30-min post-operatively. The study was divided into two time
periods; Group 1 (1995e2007); where there was no formal guidance for managing post-CEA hypertension (PEH)
and Group 2 (2008e2012); where written guidelines for treating PEH were available.
Results: 11/1024 patients in Group 1 (1.1%) suffered a stroke due to HS/ICH, compared to 0/426 patients (0.0%)
in Group 2 (p ¼ 0.02). In Group 1; intra-operative increases >100% in mean/peak MCAV and PI at 1 and 10-min
post-clamp release had positive predictive values (PPV) of 1.2%, 6.3% and 20.0% and 2.9%, 8.0% and 16.6%
respectively. Post-operatively; a >100% increase in mean and peak MCAV had a PPV of 6.3% and 2.7%
respectively.
Conclusion: We were unable to demonstrate that signiﬁcant increases in MCAV and PI were able to predict
patients at increased risk of suffering a post-operative stroke due to HS or ICH. The provision of written guidance
for managing PEH in Group 2 patients was associated with virtual abolition of ICH/HS.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Following successful carotid endarterectomy (CEA), there are
three important causes of neurological morbidity/mortality
in the early post-operative period. These include; (i) stroke
due to thromboembolism from the endarterectomy zone; (ii)
stroke secondary to the hyperperfusion syndrome and
(iii) intracranial haemorrhage. Whilst evidence suggests
that early post-operative thromboembolic stroke can beresponding author. J.E. Newman, Vascular Research Group, Division
diovascular Sciences, Clinical Sciences Building, Leicester Royal
ry, Leicester LE27LX, United Kingdom. Tel.: þ44 116 2523252;
4 116 2523179.
il address: jn139@le.ac.uk (J.E. Newman).
-5884/$ e see front matter  2013 European Society for Vascular
. Published by Elsevier Ltd. All rights reserved.
//dx.doi.org/10.1016/j.ejvs.2013.02.019prevented by adjuvant Dextran therapy1 or (more recently)
the addition of a single 75 mg dose of clopidogrel the night
before surgery in addition to routine aspirin therapy,2 it has
proved difﬁcult to prevent intracerebral haemorrhage (ICH)
or stroke due to the cerebral hyperperfusion syndrome (HS).
The haemodynamic deﬁnition of cerebral hyperperfusion
is generally accepted to be a >100% increase in cerebral
blood ﬂow velocity over baseline.3 However not all patients
will develop the clinical deﬁnition of cerebral hyperperfusion
syndrome which includes ipsilateral headache and/or
seizures and/or a focal neurological deﬁcit in the absence of
cerebral ischaemia.3
The prevalence of stroke due to HS/ICH is low (1e2%), but
its aetiology is complex and largely unstudied.4 The two
entities may, however, share a common pathophysiological
pathway that ultimately leads to neurological injury following
ischaemia or haemorrhage, depending upon a complex inter-
relationship between increasing cerebral blood ﬂow, the
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J.E. Newman et al. 563upregulation of proinﬂammatory cytokines, the release of
prothrombotic agents and increased endothelial fragility/
permeability, usually in the context of worsening
hypertension.5
A number of factors have been associated with HS/ICH.
These include; bilateral severe carotid disease, impaired
cerebral autoregulation, poorly controlled blood pressure
before surgery, increased cerebral blood ﬂowpost-operatively,
recent cerebral infarction, anticoagulant therapy, whitematter
oedema (posterior leucoencephalopathy syndrome), impaired
cerebral vascular reserve, poor collateralisation via the circle of
Willis and post-endarterectomy hypertension.4,6e10
However, because of its low prevalence, it has proved
particularly difﬁcult to identify patients at greatest risk of
suffering a stroke due to HS/ICH. One promising research
theme suggested that a signiﬁcant increase in middle
cerebral artery velocity (MCAV) and/or Pulsatility Index (PI),
measured using transcranial Doppler (TCD) ultrasound,
might identify a high-risk subgroup in whom to target
aggressive anti-hypertensive therapy post-operatively.11e13
The data supporting this hypothesis are summarised in
Table 1 and are derived from studies where increases in
MCAV/PI were used to identify patients at increased risk of
developing one or more components of the HS clinical
syndrome (ipsilateral headache, seizure, ICH or HS stroke). It
is never easy to reliably audit the true prevalence of ipsi-
lateral headache after CEA (or even seizure), so the aim of
the current study was to establish whether >100%
increases in MCAV and PI were associated with an increased
risk of suffering HS or ICH.
MATERIALS AND METHODS
This was a retrospective audit of prospectively collected
data in 1450 patients undergoing CEA with an accessible
transcranial Doppler (TCD) window between 1st October
1995 and 31st March 2012. Because ICH and HS stroke are
related to post-CEA hypertension, two consecutive time
periods were evaluated: In Group 1 (1st October 1995 to
31st December 2007) there was no written guidance for
managing post-CEA hypertension. In Group 2 (1st January
2008 to 31st March 2012) there was written guidance for
managing post-CEA hypertension, which was placed in the
case records of every CEA patient. The Leicestershire,
Northamptonshire and Rutland Research Ethics Committee
advised that this study did not fall under the remit of the
NHS Research Ethics Committee, as it was audit/service
evaluation.Ta
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Between 1st October 1995 and 30th September 2008
(Group 1), patients were usually assessed in the Vascular
Surgery Clinic and listed for CEA. During this period, it was
generally left to the referring family doctor to ensure that
hypertension was treated appropriately prior to surgery.
There were no consensus criteria for postponing CEA should
the pre-operative BP be poorly controlled, apart from
where the systolic BP was >200 mmHg. There was also no
564 European Journal of Vascular and Endovascular Surgery Volume 45 Issue 6 June/2013consistent policy regarding pre-operative statin therapy,
although most patients would have been started on a statin
prior to surgery. All patients were prescribed 75e150 mg
aspirin, which was not stopped during the peri-operative
period.
After 1st October 2008 (Group 2), a daily ‘Rapid Access
TIA’ Clinic provided single-visit CT/MR imaging and colour
Duplex ultrasound assessment of the extra-cranial carotid
arteries. All patients underwent risk factor assessment and
immediate implementation of ‘best medical therapy’ and
patients found to have an ipsilateral 50e99% stenosis were
transferred directly to the Vascular Surgery Unit for expe-
dited CEA.14 Patients were commenced on daily statin
therapy in the TIA clinic (usually 40 mg simvastatin unless
contraindicated). A 300 mg dose of aspirin was adminis-
tered along with a single 75 mg dose of clopidogrel. Aspirin
(75 mg daily) was continued throughout the peri-operative
period and all patients were prescribed a further 75 mg
dose of clopidogrel the night before surgery. Following
introduction of the ‘Rapid Access’ TIA Service on 1st
October 2008, much greater efforts were made to correct
uncontrolled hypertension (>180 mmHg systolic) prior to
surgery. Our current practice is to avoid slow acting anti-
hypertensive agents (these can be introduced post-
operatively) and we would usually prescribe 30 mg Nifedi-
pine LA e ‘Long Acting’ (adding Lisinopril 10 mg if there was
no rapid response). Patients with poorly controlled hyper-
tension (<180 mmHg) did not have their surgery delayed in
order to control blood pressure and our intention was to
treat any persisting hypertension post-operatively before
discharge. While it would be ideal to secure optimal control
of blood pressure pre-operatively, this has to be balanced
against the very high risk of recurrent stroke in the hyper-
acute period after onset of symptoms.Operation
The operative procedure has remained unchanged since
1991 (general anaesthesia, routine patching, routine
shunting, systemic heparinisation and distal intimal tacking
sutures). In patients with a trans-temporal window, TCD
monitoring was commenced following induction of anaes-
thesia using a 2 MHz head probe, which was protected by
a semi-circular headguard. The surgeon and anaesthetist
aimed to ensure that mean MCAV in the middle cerebral
artery was >15 cm/s at all times. If the MCAV was <15 cm/
s following shunt insertion, the shunt was repositioned to
exclude abutment against the distal ICA lumen. If the MCAV
remained <15 cm/s, blood pressure was therapeutically
elevated by the anaesthetist. Immediately prior to patch
closure, a 5 mm space was retained adjacent to the oriﬁce
of the external carotid artery. The shunt was removed and
all vessels were back vented and irrigated with heparinised
saline. The lumen of the endarterectomy zone was then
inspected with a ﬂexible hysteroscope (Olympus 1070-48,
OlympusUK, Southend-on-Sea, UK). Our policy was to repair
all intimal ﬂaps >3 mm and to remove any residual thrombi
from the lumen.Peri-operative TCD monitoring
Patients with an accessible TCD window underwent intra-
operative monitoring, although the policy regarding post-
operative TCD monitoring changed during the 17-year
period. In order to investigate whether increases in MCAV
could predict patients at risk of ICH or HS stroke, we report
MCAV/PI readings at similar time points as had been used in
the studies detailed in Table 1; pre-operatively (V1),
immediately pre-clamp (V2), 1 min post-clamp release (V3),
10 min post-clamp release (V4), and 30 min after entering
theatre Recovery (V5). However; because of evolving post-
operative monitoring protocols, it was not always possible
to acquire all ﬁve readings in every patient. For example;
prior to 2004, no intra-operative measurements of Peak
Systolic MCAV or PI were recorded. Data for mean MCAV
were, however, available for everyone throughout the time
period.
Between 1st October 1995 and 1st August 2006, all
patients underwent at least three hours of post-operative
TCD monitoring and anyone with high-rate embolisation
(>25 emboli in any 10 min period) received adjuvant
intravenous Dextran therapy to prevent progression onto
carotid thrombosis.1 Following a review of practice in
2006,15 the period of post-op TCD monitoring was reduced
from 3 h to 30 min. Following a second audit of practice in
August 2009 (which evaluated the effect of routine pre-
operative clopidogrel in addition to Aspirin), it was noted
that virtually no patients now required adjuvant Dextran
therapy (high-rate embolisation had all but disappeared)
and so routine post-operative monitoring was stopped.2
Accordingly, a number of Group 2 patients did not have
any TCD data available for the end-point of 30 min after
entry into the theatre recovery area.TCD endpoints for study
This study aimed to determine whether >100% increases in
MCAV or PI were predictive of an increased risk of ICH or
stroke secondary to HS (Table 2). Seizures and headache
(unless associated with a neurological deﬁcit) were not
included in this analysis, although it is accepted that these
can represent early manifestations of the hyperperfusion
syndrome.Post-operative assessment
Following recovery from anaesthesia, the patient was
transferred to theatre recovery for monitoring. Patients
were usually discharged on day two on regular aspirin
therapy (75 mg daily). No further Clopidogrel was admin-
istered unless this was mandated for other reasons (e.g.
cardiac indication etc). All patients were reviewed in the
Outpatient Department 4e6 weeks after surgery.Peri-operative BP treatment
Prior to January 2008 (Group 1), there was no consistent
policy for treating post-operative hypertension. This was left
to the discretion of the operating surgeon and the on call
Table 2. Transcranial Doppler endpoints used for the prediction of
post-operative intracranial haemorrhage or stroke due to the
hyperperfusion syndrome.
TCD based predictive criteria Deﬁnition
Mean intraopþ1 >100% >100% increase in mean
MCAV between pre-clamp
(V2) and 1 min post-clamp
release (V3)
Mean intraopþ10 >100% >100% increase in mean
MCAV between pre-clamp
(V2) and 10 min post-clamp
release (V4)
Mean postopþ30 >100% >100% increase in mean
MCAV 30 min after entry
into theatre Recovery (V5)
compared with the
pre-operative mean MCAV
velocity (V1).
Peak intraopþ1 >100% >100% increase in peak
systolic MCAV between
pre-clamp (V2) and 1 min
post-clamp release (V3)
Peak intraopþ10 >100% >100% increase in peak
systolic MCAV between
pre-clamp (V2) and 10 min
post-clamp release (V4)
Peak postopþ30 >100% >100% increase in peak
systolic MCAV 30 min after
entry into theatre Recovery
(V5) compared with the
pre-operative mean MCAV
velocity (V1).
PI intraopþ1 >100% >100% increase in Pulsatility
Index between V2 pre-clamp
(V2) and 1 min post-clamp
release (V3)
PI intraopþ10 >100% >100% increase in Pulsatility
Index between pre-clamp
(V2) and 10 min post-clamp
release (V4)
PI postopþ30 >100% >100% increase in Pulsatility
Index 30 min after entry
into theatre Recovery (V5)
compared with the
pre-operative mean MCAV
velocity (V1).
TCD ¼ transcranial Doppler, PI ¼ Pulsatility Index, MCAV ¼middle
cerebral artery velocity, V1 ¼ pre-operative TCD measurement
(mean/peak/PI), V2 ¼ pre-clamp TCD measurement, V3 ¼ 1 min
post-clamp release TCD measurement, V4 ¼ 10 min post-clamp
release TCD measurement, V5 ¼ 30 min after entering recovery
TCD measurement, Intraopþ1/10 ¼ the percentage increase in
mean/peak MCAV or PI at 1 min or 10 min post-clamp release
compared to the pre-clamp measurement, Postopþ30 ¼ the
percentage increase in mean MCAV within 30 min of entering
the recovery room compared to the pre-operative measurement.
Table 3. Guidance for the management of (i) severe
hypertension in the recovery area of theatre
(>170 mmHg) or (ii) back on ward (>160 mmHg)
in association with severe headache and/or seizures.
First line: Labetalol
100 mg Labetalol in 20 ml of 0.9% Saline. (i.e.
5 mg per ml).
Give 10 mg (2 ml) boluses slowly every two mins
up to 100 mg (i.e. 20 ml given over 20 min).
If BP remains elevated after 20 min, move to
second line agent.
If BP reduces and does not rebound, continue
regular BP observations.
If BP reduces but increases again, start infusion at
50e100 mg per hour, titrating dose to BP.
Second line: Hydralazine
10 mg Hydralazine in 10 ml of 0.9% Sodium
Chloride (i.e. 1 mg per ml).
Give 2 mg (2 ml) boluses slowly every 5 min up to
10 mg (i.e. 10 ml given over 25 min).
If BP remains elevated after 25 min, move to
third line agent.
If BP reduces and does not rebound, continue
regular BP observations.
If BP reduces but increases again, move to third
line agent
Third line: GTN
50 mg GTN in 50 ml 0.9% Sodium Chloride (i.e.
1 mg per ml).
Start infusion at 5 ml/h (5 mg/h), increasing rate
to 12 ml/h (12 mg/h), titrated to BP.
J.E. Newman et al. 565medical staff to deal with as they saw appropriate and an
indeterminate number of patients may have been dis-
charged with poorly controlled blood pressure (by modern
day standards). After 1st January 2008 (Group 2), written
guidance (Tables 3 and 4) was developed followingconsensus meetings involving vascular surgeons, anaesthe-
tists and hypertension specialists.16 These were placed in
the case records of every CEA so that they were always
available should hypertension require treatment. Patients
would only return to the ward from theatre recovery if they
were normotensive and once on the ward would have
hourly BP measurements for the ﬁrst 24-h post-op period.
Subsequently 4-hourly BP measurements would continue
till discharge. Those patients who later developed uncon-
trolled hypertension (>200 mmHg) with or without symp-
toms (headaches, seizures, new-onset neurology), would be
transferred to intensive care for invasive blood pressure
monitoring. In Group 2 patients, it was unit policy that no
patient should be discharged until their blood pressure was
adequately controlled. On occasions, this required a pro-
longed in-patient stay and additional input from hyperten-
sion specialists.Post-operative morbidity and mortality
Any patient suffering a new neurological deﬁcit was
assessed by a Neurologist/Stroke Physician and underwent
investigations to identify the likely underlying cause; (i) CT
scan (to identify ICH, patterns of white matter oedema
typically associated with HS,5 embolic cortical infarction,
haemodynamic watershed infarction); (ii) CT angiography
Table 4. Management of the patient becomes who
hypertensive on the ward (systolic
BP > 170 mmHg) but with NO headache, seizure
or focal neurological deﬁcit.
Patient is NOT normally taking anti-hypertensive
therapy
First line: Nifedipine Retard (10 mg), repeated
after 1 h if no change in BP. DO NOT use crushed
Nifedipine capsules
Second line: Bisoprolol 5.0 mg. If contra-
indicated, move to third line agent.
Third line: Ramipril 5 mg, repeated at 3 h if
necessary
Patient IS normally on anti-hypertensive
therapy
First line: Check the patient has received normal
anti-hypertensive medication. If not, administer
these.
Second line: A [ ACE inhibitor, B [ B-Blocker,
C [ Calcium Channel Blocker, D [ Diuretic
If patient is on A, add in C (Nifedipine LA 10 mg)
If patient is on C, add in A (Ramipril 5 mg)
If patient is on D, add in A (Ramipril 5 mg)
If patient is on A þ C, add in D (Bendroﬂuazide
2.5 mg)
If patient is on A þ D, add in C (Nifedipine LA
10 mg)
If patient is on A þ C þ D, add in B (Bisoprolol
5 mg)
Patient cannot swallow tablets
Pass nasogastric tube and administer appropriate
medicines in liquid form as prescribed above. In
this situation, Amlodipine should replace
Nifedipine
566 European Journal of Vascular and Endovascular Surgery Volume 45 Issue 6 June/2013(to evaluate vascular anatomy from arch to circle of Willis);
(iii) colour Duplex ultrasound (to exclude ﬁlling defects in
the operated ICA, ﬂow abnormalities suggestive of inﬂow
or outﬂow problems), (iv) TCD (diagnose ongoing emboli-
sation, very high MCAV suggestive of hyperperfusion
syndrome, inter-hemispheric MCAV asymmetry suggestive
of multiple MCA branch occlusions, absent MCA mainstemTable 5. Relationship between a >100% increase in MEAN MCAV at t
ability to predict post-operative intracranial haemorrhage and/or strok
Group 1 (1995e2007)
Pre-guidelines for post-CEA hypertension (n ¼ 1
ICH/HSS in presence
of >100% MCAV increase
ICH/HSS in presenc
of <100% MCAV in
Mean intraopþ1 1/82
PPV 1.2%
10/942
NPV 98.9%
Mean intraopþ10 2/68
PPV 2.9%
7/941
NPV 99.3%
Mean postopþ30 3/48
PPV 6.3%
3/433
NPV 99.3%
ICH/HSS ¼ intracerebral haemorrhage or hyperperfusion syndrome stro
velocity. Mean Intraopþ1/10 ¼ the percentage increase in mean MCAV
measurement. Mean Postopþ30 ¼ the percentage increase in mean M
pre-operative measurement.signal suggesting embolic occlusion of MCA). Any patient
who died underwent autopsy to identify the cause of death,
unless there was a clear diagnosis pre-mortem (e.g.
extensive intra-cranial haemorrhage).
For the purpose of this study; ICH was deﬁned by the
presence of intracranial bleeding on CT scanning or at
autopsy. A stroke due to the hyperperfusion syndrome was
deﬁned to have occurred if the neurological deﬁcit was
preceded by increasing headache and/or seizures in the
presence of normal carotid anatomy on CT angiography or
colour Duplex ultrasound, the absence of focal MCA terri-
tory infarction on CT scanning, the absence of on-going
embolisation on TCD and corroborated by the presence of
posterior fossa oedema on CT which has previously been
shown to be associated with hyperperfusion related
events.5RESULTS
1450 patients undergoing CEA with an accessible trans-
cranial window for TCD monitoring were included for
analysis. Eleven of 1024 Group 1 patients suffered a post-
operative ICH (n ¼ 7) or stroke due to HS (n ¼ 4). Of the
seven cases of ICH; four occurred whilst still an in-patient,
while three occurred after discharge (days 7, 9 and 23).
Of the four cases of stroke due to HS; three occurred whilst
still an in-patient, while one happened following discharge
(day 6). None of the Group 2 patients suffered a stroke due
to HS or ICH within 30-days of surgery. It should be noted
that none of the Group 1 patients suffering an ICH had
received Dextran in the early post-operative period,
whereas every Group 2 patient had received Clopidogrel the
night before surgery.
Table 5 details the relationship between intra-operative
and post-operative increases in mean MCAV and the prev-
alence of ICH or stroke due to the HS; stratiﬁed for whether
there were written guidelines for managing post-CEA
hypertension. Eighty-two out of 1024 patients undergoing
CEA between 1995 and 2007 had a >100% increase in intra-
operative mean MCAV one minute after clamp release
(compared to pre-clamp) but only one of these (1.2%) went
on to develop ICH or HS stroke. This compares with 2hree different time points during carotid endarterectomy and the
e due to the hyperperfusion syndrome.
024)
Group 2 (2008e2012)
After guidelines for post-CEA hypertension (n ¼ 426)
e
crease
ICH/HSS in presence
of >100% MCAV increase
ICH/HSS in presence
of <100% MCAV increase
0/21
PPV 0.0%
0/405
NPV 100%
0/12
PPV 0.0%
0/416
NPV 100%
0/15
PPV 0.0%
0/134
NPV 100%
ke, CEA ¼ carotid endarterectomy, MCAV ¼middle cerebral artery
at 1 min or 10 min post-clamp release compared to the pre-clamp
CAV within 30 min of entering the recovery room compared to the
J.E. Newman et al. 567patients who developed ICH/HS stroke out of 68 (2.9%) who
had a >100% increase in mean MCAV 10 min after clamp
release (compared to pre-clamp), and 3 out of 48 patients
(6.3%) with a >100% increase in mean MCAV 30 min after
entering theatre recovery (compared to pre-operative).
Conversely, while a larger actual number of patients
suffered ICH/HS stroke in the presence of a <100% increase
in MCAV (Table 5), the negative predictive values in each
case were >98%.
Following the introduction of written guidance for
treating post-CEA hypertension in 2008, 426 Group 2
patients underwent CEA. In this cohort (Table 5), no one
with an accessible TCD window suffered either ICH or stroke
due to HS, despite a number having signiﬁcant increases in
mean MCAV intra-operatively and/or post-operatively.
Tables 6 and 7 detail the ability of the full range of TCD
endpoints (mean MCAV, peak MCAV, PI) to predict an
increased risk of ICH or HS; relative to whether the patients
were in Group 1 (Table 6) or Group 2 (Table 7). As can be
seen, none were able to reliably predict who would go on to
suffer ICH/HS stroke.
Between 1995 and 2012, 11 patients with an accessible
TCD window suffered ICS/HS stroke following CEA; eight of
whom had a systolic BP > 200 mmHg at the time of onset
of symptoms. From 1995 to 2007 (where there were no
written guidelines for treating post-CEA hypertension), the
prevalence of ICH/HS was 1.1% (11/1024), compared
to 0.0% (0/429) following introduction of the post-CEA
hypertension guidelines (p ¼ 0.02).DISCUSSION
This study was unable to demonstrate that a >100%
increase in either MCAV or PI following restoration of ﬂow
(intra-operatively or post-operatively) was predictive of
a signiﬁcantly increased risk of ICH/HS stroke in a large
cohort of patients following CEA.
The relationship between a doubling of intraoperative
cerebral blood ﬂow and the development of the hyper-
perfusion syndrome was ﬁrst described by Sundt in 1981.3
Subsequent studies have corroborated this relationship
through TCD, Xenon-133 and single photon emission CT
(SPECT).4,11,16 More recently a post-operative doubling in
MCAV (using TCD) has been proposed as being more
predictive of suffering the HS syndrome, with the absence
of a >100% increase almost excluding the likelihood of its
development. This led the authors to suggest that only
those with >100% increases in MCAV warranted aggressive
monitoring and treatment of post-CEA hypertension.13
Prior to the introduction of the post-CEA hypertension
protocol in January 2008, the incidence of HS stroke/ICH in
the Leicester Vascular Unit was 1.1% (11/1024 patients).
This is similar to the ﬁndings of a recent meta-analysis,
which reported a 1.0% prevalence of HS and a 0.5% prev-
alence of ICH17 and is broadly comparable with similar
studies investigating TCD derived MCAV changes after CEA
(Table 1). The positive predictive value (PPV) of TCD
measurements for suffering HS stroke/ICH was 1.2%e2.9%for an intraoperative mean MCAV >100%; 6.3%e8.0% for
intraoperative peak MCAV increases >100% and 16.6%e
20.0% for intraoperative PI increases. These PPVs, however,
compare unfavourably with previously reported values of
13% for intraoperative increases in mean MCAV >100%13
and 11e80% PPVs for increases in intraoperative peak
MCAV and PI increases >100%.11,12 This is most likely to
reﬂect the fact that the end-point in the current study was
the prediction of HS stroke/ICH, rather than HS syndrome
(headache, seizures, ICH, stroke). Our post-operative mean
MCAV increases >100% had a PPV of only 6.3% with only 3
of 48 patients with a >100% increase in MCAV going on to
develop HS/ICH. In Pennekamp’s recent report (and the
catalyst for the current study), the PPV for a >100%
increase in MCAV post-operatively was 41% with 9/22
patients developing signs or symptoms of HS.13
With such a low incidence of HS/ICH after CEA, the
investigation of factors that may be predictive of its
occurrence is difﬁcult. To date, our study represents the
largest cohort of patients with TCD measurements of MCAV
who have undergone CEA, spanning 17-years of data
collection. Although retrospective, all the intra-operative
and post-operative data for the study were collected
prospectively. Due to the Departments’ changing protocol
for peri-operative TCD data collection, however, it was not
possible to report all TCD endpoints for every patient
throughout the 17 year period of study. However with
standardisation of the operative procedure since 1991, any
potential for confounding intra-operative factors that may
affect the development of post-CEA hypertension or HS/ICH
would be expected to affect the entire study cohort. A
possible limitation of the study methodology was the
introduction of guidelines for the administration of statins
and antiplatelet agents in the TIA clinic at the same time as
the implementation of the hypertension protocol. Prior to
this, prescribing of best medical therapy had been at the
discretion of the operating clinician. It should however be
assumed that all patients would have been appropriately
medicated with both an antiplatelet and statin according to
best medical practice.
The assumption that impaired cerebral autoregulation
accounts for the development of ICH may represent an
overly simplistic view, with a number of series having re-
ported patients with ICH and no peri-operative increase in
cerebral blood ﬂow or blood pressure. In Piepgras series of
14 patients with post-CEA ICH, 9 had documented hyper-
perfusion (>100% increase in MACV).18 In another study
using Xenon-133, 4/7 patients with symptoms of HS had
MCAV ﬂows >100%.10 Schroeder similarly found a doubling
in cerebral blood ﬂow post-surgery in those developing ICH
in 2/4 patients in their series.4 A more recent audit of
patients with seizures and symptoms of HS post-CEA found
an intra-operative and post-operative >100% increase in
MCAV in 3/8 patients. However, what was consistent in the
latter series was that all eight patients had suffered post-
CEA hypertension (SBP > 170 mmHg), while 6/8 patients
had a SBP >200 mmHg.7 In addition, Pennekamp observed
post-CEA hypertension in all 10 patients who developed
Table 6. TCD based predictors for identifying patients at higher risk of suffering stroke due to the hyperperfusion syndrome or intracranial haemorrhage after carotid endarterectomy between
October 1995 and December 2007 when there were no guidelines for managing post-CEA hypertension.
TCD predictive criteria
used in the study
Number meeting
TCD criteria
Number suffering
HS or ICH or
seizures (S) after CEA
Was there a clear
policy for managing
post-CEA hypertension?
Met TCD criteria &
suffered HS/ICH
Did not meet
TCD criteria but
suffered HS/ICH
Did not meet TCD
criteria and did not
suffer HS/ICH
Mean intraopþ1 >100% 82/1024 (8%) 11/1024 (1.1%) No 1/82
PPV 1.2%
10/942 (1.1%) 932/942
NPV ¼ 98.9%
Mean intraopþ10 >100% 68/1009 (6.7%) 9/1009 (0.9%) No 2/68
PPV ¼ 2.9%
7/941 (0.7%) 934/941
NPV ¼ 99.3%
Mean postopþ30 >100% 48/481 (10%) 6/481 (1.2%) No 3/48
PPV ¼ 6.3%
3/433 (0.7%) 430/433
NPV ¼ 99.3%
Peak intraopþ1 >100% 32/263 (12.2%) 4/263 (1.5%) No 2/32
PPV ¼ 6.3%
1/231 (0.4%) 229/231
NPV ¼ 99.5%
Peak intraopþ10 >100% 25/270 (9.3%) 3/270 (1.15) No 2/25
PPV ¼ 8.0%
1/245 (0.4%) 244/245
NPV ¼ 99.5%
Peak postopþ30 >100% 37/251 (14.7%) 3/251 (1.2%) No 1/37
PPV ¼ 2.7%
2/214 (0.9%) 212/214
NPV ¼ 99.0%
PI intra-opþ1 >100% 5/92 (5.4%) 5/92 (5.4%) No 1/5
PPV ¼ 20%
4/87 (4.6%) 83/87
NPV ¼ 95.4%
PI intraopþ10 >100% 6/103 (5.8%) 6/97 (6.2%) No 1/6
PPV ¼ 16.6%
5/97 (5.2%) 92/97
NPV ¼ 94.8%
PI postopþ30 >100% 1/229 (0.4%) 1/229 0.4%) No 0/1
PPV ¼ 0.0%
1/228 (0.4%) 227/228
NPV ¼ 99.5%
TCD ¼ transcranial Doppler, CEA ¼ carotid endarterectomy, HS ¼ hyperperfusion syndrome, ICH ¼ intracranial haemorrhage, PI ¼ Pulsatility Index, PPV ¼ positive predictive value,
NPV ¼ negative predictive value, Intraopþ1/10 ¼ the percentage increase in mean/peak MCAV or PI at 1 min or 10 min post-clamp release compared to the pre-clamp measurement,
Postopþ30 ¼ the percentage increase in mean MCAV within 30 min of entering the recovery room compared to the pre-operative measurement.
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Table 7. TCD based predictors for identifying patients at higher risk of suffering stroke due to the hyperperfusion syndrome or intracranial haemorrhage after carotid endarterectomy between
January 2008 and March 2012 when there were published guidelines for managing post-CEA hypertension.
TCD predictive criteria used
in the study
Number meeting
TCD criteria
Number suffering HS
or ICH or seizures (S)
after CEA
Was there a clear
policy for managing
post-CEA hypertension?
Met TCD criteria &
suffered HS/ICH
Did not meet TCD
criteria but suffered
HS/ICH
Did not meet TCD
criteria and did not
suffer HS/ICH
Mean intraopþ1 >100% 21/426 (4.9%) 0/426 (0.0%) Yes 0/21
PPV ¼ 0.0%
0/405 (0.0%) 405/405
NPV ¼ 100%
Mean intraopþ10 >100% 12/428 (2.8%) 0/428 (0.0%) Yes 0/12
PPV ¼ 0.0%
0/416 (0.0%) 416/416
NPV ¼ 100%
Mean postopþ30 >100% 15/149 (10.1%) 0/149 (0.0%) Yes 0/15
PPV ¼ 0.0%
0/134 (0.0%) 134/134
NPV ¼ 100%
Peak intraopþ1 >100% 39/408 (9.6%) 0/408 (0.0%) Yes 0/39
PPV ¼ 0.0%
0/369 (0.0%) 369/369
NPV ¼ 100%
Peak intraopþ10 >100% 39/412 (9.5%) 0/412 (0.0%) Yes 0/39
PPV ¼ 0.0%
0/373 (0.0%) 373/373
NPV ¼ 100%
Peak postopþ30 >100% 12/129 (9.3%) 0/129 (0.0%) Yes 0/12
PPV ¼ 0.0%
0/117 (0.0%) 117/117
(NPV ¼ 100%
PI intra-opþ1 >100% 13/318 (4.1%) 0/318 (0.0%) Yes 0/13
PPV ¼ 0.0%
0/305 (0.0%) 305/305
NPV ¼ 100%
PI intraopþ10 >100% 12/321 (3.7%) 0/321 (0.0%) Yes 0/12 (0.0%) 0/309 (0.0%) 309/309
NPV ¼ 100%
PI postopþ30 >100% 3/119 (2.5%) 0/119 (0.0%) Yes 0/3
PPV ¼ 0.0%
0/116 (0.0%) 116/116
NPV ¼ 100%
TCD ¼ transcranial Doppler, CEA ¼ carotid endarterectomy, HS ¼ hyperperfusion syndrome, ICH ¼ intracranial haemorrhage, PI ¼ Pulsatility Index, PPV ¼ positive predictive value,
NPV ¼ negative predictive value, Intraopþ1/10 ¼ the percentage increase in mean/peak MCAV or PI at 1 min or 10 min post-clamp release compared to the pre-clamp measurement,
Postopþ30 ¼ the percentage increase in mean MCAV within 30 min of entering the recovery room compared to the pre-operative measurement.
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<100% post-operatively.13
Hypertensive encephalopathy (HE) and hyperperfusion
syndrome have virtually identical clinical presentations
(headache, confusion, seizures, neurological impairment)
and pathological features (oedema, ﬁbrinoid necrosis,
arteriolar thrombosis, micro-infarcts and petechial break-
through haemorrhages) and may simply represent different
outcomes of a common pathological process.5,19 In patients
with defective cerebral autoregulation, changes in cerebral
blood ﬂow are proportional to MAP (minus intracranial
pressure) and even moderate rises in SBP could theoreti-
cally lead to HS and ICH. However, in the presence of
preserved cerebral autoregulation, a sudden increase in
blood pressure can exceed the cerebral autoregulation
threshold (wMAP 140 mmHg) at which point cerebral
blood ﬂow is proportional to MAP, there is forced vasodi-
lation, endothelial dysfunction and subsequent oedema
formation as ﬂuid leaks through the capillary walls.20 In the
latter example, (in the absence of post-CEA hypertension) it
is unlikely that there would be any identiﬁable TCD changes
in MCAV that might then be predicative of HS, as cerebral
autoregulation is preserved.
More recently, a study using magnetic resonance imaging
(MRI) with diffusion-weighted imaging and perfusion-
weighted imaging, found only a moderate (20e44%) ipsi-
lateral hemispheric hyperperfusion in patients with symp-
toms of HS or ICH. Although all had ‘higher than normal BP’
(according to the authors), this was ‘only striking’ in only 2
of the 4 patients. The authors proposed that the ‘normal
perfusion pressure breakthrough’ hypothesis21 could be the
explanation for the development of HS in the absence of
severe hypertension; i.e. mechanically weaker capillaries
that were more vulnerable to break through by the dis-
tending forces on reperfusion.22 The likelihood is that there
are patients exhibiting a spectrum of cerebral autor-
egulation responses ranging from preserved, through
partially impaired and on to dysfunctional, and that in the
presence of either moderate or severe post-CEA hyperten-
sion, patients may become susceptible to the development
of HE/HS and ICH. This small cohort of patients who exhibit
symptoms of HS despite normotension/moderate hyper-
tension (SBP < 160 mmHg),17 would likely beneﬁt from
further reduction in systolic BP till symptoms resolve.
In conclusion, a TCD measurement of a >100% increase
in mean or peak MCAV or PI was not associated with
a signiﬁcantly increased risk of suffering a post-operative
stroke due to HS or ICH. However, the absence of
a >100% increase in MCAV or PI did mean that the patient
was highly unlikely to suffer HS stroke or ICH. Others have
suggested that the absence of a >100% increase in MCAV/
PI could reduce the need for aggressive PEH treatment,11
but as we have now stopped all post-operative TCD moni-
toring (because peri-operative Clopidogrel has all but
abolished stroke due to post-operative carotid thrombosis),
this is not really a practical option for us (and many others
who ﬁnd TCD cumbersome). By contrast, we have found
that the provision of post carotid endarterectomyhypertension treatment guidelines was easy to implement
and may become the easiest way of preventing HS stroke/
ICH and possibly cardiac related complications as well.CONFLICT OF INTEREST/FUNDING
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